Pfizer Receives U.S. FDA Approval for Its Oncology Biosimilar, ZIRABEV™ (bevacizumab-bvzr)

28. Juni 2019 INDIZES USA

“Biosimilars like ZIRABEV can help increase access to impactful therapies, driving market competition that may ultimately lower …
(Orginal – Story lesen…)

Tags: dow jones nasdaq s&p 500

You may also like...